Familial isolated arrhythmogenic right ventricular dysplasia
MONDO:0016342Familial isolated arrhythmogenic right ventricular dysplasia (ARVC) is the familial autosomal dominant form of ARVC, a heart muscle disease characterized by life-threatening ventricular arrhythmias with left bundle branch block configuration that may manifest with palpitations, ventricular tachycardia, syncope and sudden fatal attacks, and that is due to dystrophy and fibro-fatty replacement of the right ventricular myocardium that may lead to right ventricular aneurysms.
Also known as: familial isolated ARVC, familial isolated ARVD, familial isolated arrhythmogenic right ventricular cardiomyopathy, familial isolated arrhythmogenic right ventricular dysplasia, familial isolated arrhythmogenic ventricular cardiomyopathy, familial isolated arrhythmogenic ventricular dysplasia
16 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could a short course of steroids calm a dangerous heart rhythm?
Disease control ENROLLING_BY_INVITATIONThis trial tests whether an 8-week course of the immunosuppressive drug prednisone can reduce episodes of ventricular tachycardia (a potentially fatal fast heart rhythm) and improve heart function in people with non-ischemic cardiomyopathy and confirmed heart inflammation. Partic…
Phase: PHASE4 • Sponsor: Roderick Tung • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Heart rhythm showdown: ablation may beat drugs for ventricular tachycardia
Disease control OngoingThis trial tests whether a procedure called catheter ablation works better than anti-arrhythmic drugs for people with structural heart disease who have had a dangerous fast heart rhythm (ventricular tachycardia). About 162 participants will be randomly assigned to either ablation…
Phase: NA • Sponsor: Western Sydney Local Health District • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Gene therapy trial targets rare heart disease in 10 patients
Disease control OngoingThis early-stage trial tests a gene therapy called LX2020 for people with a heart condition called arrhythmogenic cardiomyopathy, caused by a change in the PKP2 gene. The study involves 10 adults who already have a defibrillator implanted. The main goal is to see if the treatment…
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Gene therapy for rare heart disease passes early safety check
Disease control ENROLLING_BY_INVITATIONThis study follows 10 people who already received LX2020 gene therapy for arrhythmogenic cardiomyopathy caused by a PKP2 gene mutation. Researchers will monitor them for years to see if the treatment remains safe and continues to help control the disease. The goal is to understan…
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Super MRI could spot hidden heart damage
Diagnosis OngoingThis study tests whether a new, more powerful 7 Tesla MRI can better detect scarring and swelling in the heart muscle of people with cardiomyopathy. Researchers will scan 13 adults aged 20-70 to see if the higher-resolution images improve diagnosis. The goal is to see if this adv…
Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC